DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritisTools Glossop, John R., Nixon, Nicola B., Emes, Richard D., Sim, Julius, Packman, Jon C., Mattey, Derek L., Farrell, William E. and Fryer, Anthony A. (2016) DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis. Epigenomics . ISSN 1750-192X Full text not available from this repository.
Official URL: http://www.futuremedicine.com/doi/10.2217/epi-2016-0042
AbstractAim: A proof-of-concept study to explore whether DNA methylation at first diagnosis is associated with response to disease-modifying antirheumatic drugs (DMARDs) in patients with early rheumatoid arthritis (RA). Patients & methods: DNA methylation was quantified in T-lymphocytes from 46 treatment-naive patients using HumanMethylation450 BeadChips. Treatment response was determined in 6 months using the European League Against Rheumatism (EULAR) response criteria. Results: Initial filtering identified 21 cytosine-phosphate-guanines (CpGs) that were differentially methylated between responders and nonresponders. After conservative adjustment for multiple testing, six sites remained statistically significant, of which four showed high sensitivity and/or specificity (≥75%) for response to treatment. Moreover, methylation at two sites in combination was the strongest factor associated with response (80.0% sensitivity, 90.9% specificity, AUC 0.85). Conclusion: DNA methylation at diagnosis is associated with disease-modifying antirheumatic drug treatment response in early RA.
Actions (Archive Staff Only)
|
Tools
Tools
